Kyverna Therapeutics, Inc.
KYTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001994702
No open-market purchases or sales by Kyverna Therapeutics, Inc. insiders were filed in the last 90 days; 120 institutions reported holding it in 13F filings for Q2 2026, worth $335.1M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Kyverna Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 99
- +27 vs. Q3 2025
- Shares held
- 34.1M
- +16.0M (+88.1%) vs. Q3 2025
- Total value
- $320.8M
- +$212.0M (+194.8%) vs. Q3 2025
- New holders
- 36
- 29 more added
- Sold out
- 9
- 21 more reduced
3 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KYTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 120 | $335.1M |
| Q1 2026 | 111 | $300.5M |
| Q4 2025 | 99 | $320.8M |
| Q3 2025 | 75 | $136.1M |
| Q2 2025 | 79 | $71.2M |
| Q1 2025 | 87 | $49.8M |
| Q4 2024 | 88 | $108.0M |
| Q3 2024 | 94 | $138.3M |
| Q2 2024 | 88 | $239.7M |
| Q1 2024 | 90 | $762.3M |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Kyverna Therapeutics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Catalio Capital Management, LP | 0 | $0 | 0.00% | −586,909−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −19,438−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −15,109−100.0% | Sold out |
| AQR Capital Management LLC | 0 | $0 | 0.00% | −13,542−100.0% | Sold out |
| Ameriprise Financial Inc | 0 | $0 | 0.00% | −12,882−100.0% | Sold out |
| Public Employees Retirement System of Ohio | 0 | $0 | 0.00% | −4,600−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −86−100.0% | Sold out |
| IFP Advisors, Inc | 0 | $0 | 0.00% | −16−100.0% | Sold out |
| Vida Ventures Advisors, LLC | – | – | – | – | Not filed |
| Cubist Systematic Strategies, LLC | – | – | – | – | Not filed |
| Point72 Asia (Singapore) Pte. Ltd. | – | – | – | – | Not filed |